With the first goal to investigate the comparative effectiveness of pralsetinib relative to other therapies, we had to consider that since the prevalence of RET fusions is low in NSCLC (1–2%)10, using RWD for studies involving patients with RET fusion-positive status would be challenging. Here, RET is linked to non-small cell lung carcinoma.